Skip to main content
Erschienen in: Medical Oncology 6/2020

01.06.2020 | Short Communication

Whole genome sequencing of colorectal neuroendocrine tumors and in-depth mutational analyses

verfasst von: Ting-ting Wang, Junyang Lu, Lai Xu, Huanwen Wu, Dianxin Lin, Zhihong Wu, Yi Xiao

Erschienen in: Medical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Colorectal neuroendocrine tumors (NETs) are rare neoplasms and studies on colorectal NETs are relatively few compared to other tumors. To better understand the pathogenesis of this tumor, we performed whole-genome sequencing and follow-up verification using Sanger sequencing of the colorectal NETs and paired para-tumor tissue. We analyzed the features of the gene mutation spectrum and mutation signature patterns, and analyzed the four pathways that were altered by gene mutation in pancreatic neuroendocrine tumors, including DNA damage and repair, chromatin remodeling, telomere maintenance and mTOR signaling activation. We found that PARP4 which is related to the DNA damage and repair pathway; TSC2, which is related to the mTOR signaling activation pathway; and SLX1A, which is related to telomere maintenance, were mutated in colorectal NETs. Our data analyzed characteristics of gene mutation in colorectal NETs at the whole-genome level, and may help to better understand the pathogenesis of colorectal NETs and may be helpful for potential tumor therapy in the future.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Amin MB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRef Amin MB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRef
2.
Zurück zum Zitat Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–422.CrossRef Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–422.CrossRef
3.
Zurück zum Zitat Takizawa N, et al. Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. Hum Pathol. 2015;46(12):1890–900.CrossRef Takizawa N, et al. Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. Hum Pathol. 2015;46(12):1890–900.CrossRef
4.
Zurück zum Zitat Klimstra DS, Capella C, Arnold R, et al. Neuroendocrine neoplasms of the colon and rectum. In: Bosaman FT, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC Press; 2010. p. 174–177. Klimstra DS, Capella C, Arnold R, et al. Neuroendocrine neoplasms of the colon and rectum. In: Bosaman FT, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC Press; 2010. p. 174–177.
5.
Zurück zum Zitat Rindi G, Arnold R, Bosman FT, Bosman T, Carneiro F, Hruban R, Theise N, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, editor. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 13–14. Rindi G, Arnold R, Bosman FT, Bosman T, Carneiro F, Hruban R, Theise N, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, editor. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 13–14.
6.
Zurück zum Zitat La Rosa S, et al. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36(4):601–11.CrossRef La Rosa S, et al. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36(4):601–11.CrossRef
7.
Zurück zum Zitat Liu S, et al. Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2013;6(6):1641–5.CrossRef Liu S, et al. Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2013;6(6):1641–5.CrossRef
8.
Zurück zum Zitat Pizzi S, et al. Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of beta-catenin and chromosomal instability. Endocr Relat Cancer. 2008;15(4):1013–24.CrossRef Pizzi S, et al. Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of beta-catenin and chromosomal instability. Endocr Relat Cancer. 2008;15(4):1013–24.CrossRef
9.
Zurück zum Zitat Vortmeyer AO, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89(19):1448–533.CrossRef Vortmeyer AO, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst. 1997;89(19):1448–533.CrossRef
10.
Zurück zum Zitat Woischke C, et al. In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol. 2017;30(1):95–103.CrossRef Woischke C, et al. In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol. 2017;30(1):95–103.CrossRef
11.
Zurück zum Zitat Scarpa A, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.CrossRef Scarpa A, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.CrossRef
13.
Zurück zum Zitat Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.CrossRef Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.CrossRef
14.
Zurück zum Zitat Kickhoefer VA, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol. 1999;146(5):917–28.CrossRef Kickhoefer VA, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol. 1999;146(5):917–28.CrossRef
15.
Zurück zum Zitat Ikeda Y, et al. Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocr Relat Cancer. 2016;23(3):171–9.CrossRef Ikeda Y, et al. Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocr Relat Cancer. 2016;23(3):171–9.CrossRef
16.
Zurück zum Zitat Alimirzaie S, et al. Mutations in known and novel cancer susceptibility genes in young patients with pancreatic cancer. Arch Iran Med. 2018;21(6):228–33.PubMed Alimirzaie S, et al. Mutations in known and novel cancer susceptibility genes in young patients with pancreatic cancer. Arch Iran Med. 2018;21(6):228–33.PubMed
17.
Zurück zum Zitat Patil V, Pal J, Somasundaram K. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget. 2015;6(41):43452–71.CrossRef Patil V, Pal J, Somasundaram K. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget. 2015;6(41):43452–71.CrossRef
18.
Zurück zum Zitat Wu K, et al. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun. 2015;6:10131.CrossRef Wu K, et al. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun. 2015;6:10131.CrossRef
Metadaten
Titel
Whole genome sequencing of colorectal neuroendocrine tumors and in-depth mutational analyses
verfasst von
Ting-ting Wang
Junyang Lu
Lai Xu
Huanwen Wu
Dianxin Lin
Zhihong Wu
Yi Xiao
Publikationsdatum
01.06.2020
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 6/2020
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01356-y

Weitere Artikel der Ausgabe 6/2020

Medical Oncology 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.